Dyne Therapeutics Inc. reported additional positive cardiopulmonary analyses from the ongoing Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy patients amenable to exon 51 skipping. In participants randomized to z-rostudirsen at baseline with available data, the company said forced vital capacity percent predicted improved through 24 months versus expected declines from published natural history, and cardiac measures including circumferential strain and left ventricular ejection fraction showed improvements versus expected worsening/declines. The new 24-month analyses are being presented in a late-breaking poster at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (March 8–11, 2026).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603081800PRIMZONEFULLFEED9667918) on March 08, 2026, and is solely responsible for the information contained therein.